Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation
Daniele Pastori(Sapienza University of Rome), Francesco Violi(Sapienza University of Rome), Simona Bartimoccia(Sapienza University of Rome), Gregory Y.H. Lip(University of Liverpool), Roberto Carnevale(Sapienza University of Rome), Cristina Nocella(Sapienza University of Rome), Roberto Cangemi(Sapienza University of Rome), Alessio Farcomeni(Department of Public Health), Tommasa Vicario(Sapienza University of Rome), Pasquale Pignatelli(Sapienza University of Rome), William R. Hiatt(University of Colorado Denver), Tommaso Bucci(University of Liverpool)
Cited by 32
Related Papers
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
|European Journal of Heart Failure|2012|2.6k
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
|European Heart Journal|2016|2.5k
2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed Under the Auspices of the ESC Committee for Practice Guidelines
|European Journal of Heart Failure|2016|1.8k
Antithrombotic Therapy for Atrial Fibrillation
|CHEST Journal|2012|919